CHA Biotech Co. Ltd (085660) - Net Assets
Based on the latest financial reports, CHA Biotech Co. Ltd (085660) has net assets worth ₩1.02 Trillion KRW (≈ $689.47 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩2.79 Trillion ≈ $1.89 Billion USD) and total liabilities (₩1.77 Trillion ≈ $1.20 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore CHA Biotech Co. Ltd (085660) total assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩1.02 Trillion |
| % of Total Assets | 36.52% |
| Annual Growth Rate | 14.3% |
| 5-Year Change | 77.45% |
| 10-Year Change | 182.64% |
| Growth Volatility | 59.1 |
CHA Biotech Co. Ltd - Net Assets Trend (2008–2025)
This chart illustrates how CHA Biotech Co. Ltd's net assets have evolved over time, based on quarterly financial data. Check tangible net worth ratio of CHA Biotech Co. Ltd to evaluate the tangible quality of the company's equity base.
Annual Net Assets for CHA Biotech Co. Ltd (2008–2025)
The table below shows the annual net assets of CHA Biotech Co. Ltd from 2008 to 2025. For live valuation and market cap data, see CHA Biotech Co. Ltd market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩809.25 Billion ≈ $548.42 Million |
+184.26% |
| 2024-12-31 | ₩284.69 Billion ≈ $192.93 Million |
-56.62% |
| 2023-12-31 | ₩656.33 Billion ≈ $444.79 Million |
+124.98% |
| 2022-12-31 | ₩291.73 Billion ≈ $197.70 Million |
-36.03% |
| 2021-12-31 | ₩456.06 Billion ≈ $309.06 Million |
+28.43% |
| 2020-12-31 | ₩355.09 Billion ≈ $240.64 Million |
-5.86% |
| 2019-12-31 | ₩377.18 Billion ≈ $255.61 Million |
+15.35% |
| 2018-12-31 | ₩326.99 Billion ≈ $221.60 Million |
+41.71% |
| 2017-12-31 | ₩230.74 Billion ≈ $156.37 Million |
-19.41% |
| 2016-12-31 | ₩286.32 Billion ≈ $194.04 Million |
-1.30% |
| 2015-12-31 | ₩290.10 Billion ≈ $196.60 Million |
-33.68% |
| 2014-12-31 | ₩437.45 Billion ≈ $296.46 Million |
-14.62% |
| 2013-12-31 | ₩512.34 Billion ≈ $347.21 Million |
+54.59% |
| 2012-12-31 | ₩331.41 Billion ≈ $224.59 Million |
+16.10% |
| 2011-12-31 | ₩285.46 Billion ≈ $193.45 Million |
+80.40% |
| 2010-12-31 | ₩158.24 Billion ≈ $107.24 Million |
+25.98% |
| 2009-12-31 | ₩125.61 Billion ≈ $85.12 Million |
+50.59% |
| 2008-12-31 | ₩83.41 Billion ≈ $56.52 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to CHA Biotech Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 27340.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩164.80 Billion | 54.10% |
| Other Components | ₩139.81 Billion | 45.90% |
| Total Equity | ₩304.61 Billion | 100.00% |
CHA Biotech Co. Ltd Competitors by Market Cap
The table below lists competitors of CHA Biotech Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bansal Wire Industries Ltd
NSE:BANSALWIRE
|
$532.73 Million |
|
Gresgying Digital Energy Technology Co Ltd
SHG:600212
|
$532.80 Million |
|
Amos Luzon Development and Energy Group Ltd
TA:LUZN
|
$532.82 Million |
|
Societe de la Tour Eiffel SA
PA:EIFF
|
$532.82 Million |
|
Nanjing Develop Advanced Manufacturing Co Ltd
SHG:688377
|
$532.34 Million |
|
Sarkuysan Elektrolitik Bakir Sanayi ve Ticaret AS
IS:SARKY
|
$532.16 Million |
|
Invesco Mortgage Capital Inc
NYSE:IVR
|
$531.97 Million |
|
Datamatics Global Services Limited
NSE:DATAMATICS
|
$531.86 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CHA Biotech Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 284,688,978,290 to 304,608,524,760, a change of 19,919,546,470 (7.0%).
- Net loss of 109,876,117,780 reduced equity.
- New share issuances of 181,730,635,060 increased equity.
- Other factors decreased equity by 51,934,970,810.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-109.88 Billion | -36.07% |
| Share Issuances | ₩181.73 Billion | +59.66% |
| Other Changes | ₩-51.93 Billion | -17.05% |
| Total Change | ₩- | 7.00% |
Book Value vs Market Value Analysis
This analysis compares CHA Biotech Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.58x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.46x to 2.58x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩5784.92 | ₩8450.00 | x |
| 2017-12-31 | ₩4599.52 | ₩8450.00 | x |
| 2018-12-31 | ₩6231.05 | ₩8450.00 | x |
| 2019-12-31 | ₩7187.10 | ₩8450.00 | x |
| 2020-12-31 | ₩6757.39 | ₩8450.00 | x |
| 2021-12-31 | ₩8106.14 | ₩8450.00 | x |
| 2022-12-31 | ₩5184.66 | ₩8450.00 | x |
| 2023-12-31 | ₩4996.00 | ₩8450.00 | x |
| 2024-12-31 | ₩4695.25 | ₩8450.00 | x |
| 2025-12-31 | ₩3276.43 | ₩8450.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CHA Biotech Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -36.07%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -8.66%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 8.36x
- Recent ROE (-36.07%) is below the historical average (-2.02%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 5.35% | 6.26% | 0.69x | 1.25x | ₩-3.88 Billion |
| 2009 | 4.37% | 1.51% | 1.57x | 1.83x | ₩-7.02 Billion |
| 2010 | 3.23% | 1.34% | 1.14x | 2.11x | ₩-10.72 Billion |
| 2011 | 1.41% | 1.19% | 0.71x | 1.67x | ₩-24.43 Billion |
| 2012 | 7.94% | 5.30% | 0.89x | 1.68x | ₩-6.33 Billion |
| 2013 | 6.63% | 4.82% | 0.77x | 1.79x | ₩-12.93 Billion |
| 2014 | 0.96% | 0.83% | 0.56x | 2.09x | ₩-26.87 Billion |
| 2015 | -5.16% | -3.80% | 0.61x | 2.22x | ₩-43.97 Billion |
| 2016 | 5.90% | 3.76% | 0.58x | 2.69x | ₩-11.75 Billion |
| 2017 | -20.15% | -11.14% | 0.53x | 3.44x | ₩-69.58 Billion |
| 2018 | 7.46% | 4.99% | 0.52x | 2.90x | ₩-8.31 Billion |
| 2019 | 12.29% | 8.67% | 0.46x | 3.08x | ₩8.66 Billion |
| 2020 | -5.25% | -2.81% | 0.51x | 3.70x | ₩-54.17 Billion |
| 2021 | -3.06% | -1.92% | 0.47x | 3.37x | ₩-59.57 Billion |
| 2022 | -16.30% | -5.63% | 0.53x | 5.51x | ₩-76.72 Billion |
| 2023 | -3.00% | -0.88% | 0.55x | 6.13x | ₩-36.57 Billion |
| 2024 | -2.83% | -0.77% | 0.48x | 7.71x | ₩-36.52 Billion |
| 2025 | -36.07% | -8.66% | 0.50x | 8.36x | ₩-140.34 Billion |
Industry Comparison
This section compares CHA Biotech Co. Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $357,982,845,938
- Average return on equity (ROE) among peers: -7.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CHA Biotech Co. Ltd (085660) | ₩1.02 Trillion | 5.35% | 1.74x | $532.39 Million |
| ORIENTBIO Inc. (002630) | $61.85 Billion | -15.44% | 1.26x | $71.52 Million |
| Green Cross (005250) | $1.31 Trillion | 5.00% | 0.57x | $283.20 Million |
| Green Cross Holdings Preference Shares (005257) | $1.76 Trillion | -3.94% | 1.31x | $2.29 Million |
| Pharmicell (005690) | $76.66 Billion | 10.78% | 0.43x | $411.92 Million |
| GeneOne Life Science Inc (011000) | $35.85 Billion | -43.51% | 0.83x | $164.07 Million |
| HLB Co. Ltd (028300) | $184.89 Billion | -24.01% | 0.96x | $2.76 Billion |
| Mgenplus Co. Ltd. (032790) | $21.42 Billion | 10.29% | 1.07x | $16.13 Million |
| Daesung Microbiological Labs. Co. Ltd (036480) | $29.01 Billion | 15.49% | 0.23x | $15.71 Million |
| Seoulin Bioscience Co.Ltd (038070) | $53.72 Billion | 4.89% | 0.32x | $24.62 Million |
| Hyundai Bioscience Co. Ltd (048410) | $45.27 Billion | -32.03% | 0.17x | $384.00 Million |
About CHA Biotech Co. Ltd
Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising f… Read more